scorecardresearch
Follow Us:
Wednesday, September 30, 2020

Coronavirus vaccine: ‘Australian shot shows promising results in animal trials’

Australian University Coronavirus (COVID-19) Vaccine: According to findings, the vaccine provided protection against virus reproduction in hamster models, and reduced lung inflammation, following exposure to the virus.

By: PTI | Melbourne | Updated: August 27, 2020 8:44:27 am
Coronavirus vaccine, UNICEF, vaccine quantities for COVID-19, Covid vaccines production, Drugmakers Covid vaccine, world newsCapacity is expected to reach 610 million doses by the end of this year, Zheng Zhongwei from the National Health Commission said. (Representational)

A COVID-19 vaccine candidate being developed by Australia’s University of Queensland has shown “positive” results against the novel coronavirus in preclinical tests, raising hopes for its potential effectiveness and manufacturability, the varsity said on Wednesday.

According to the yet-to-be published findings, the vaccine combined with the Seqirus MF59 adjuvant, provided protection against virus reproduction in hamster models, and reduced lung inflammation, following exposure to the virus.

Associate Professor Keith Chappell, who is the project co-leader, has reported to the International Society for Vaccines on the data from animal trials conducted by Viroclinics-DDL in the Netherlands, according to a statement.

“The neutralising immune response created by our molecular clamp vaccine in animal models was better than the average level of antibodies found in patients who have recovered from COVID-19,” Chappell said.

“It also induces a strong T-cell response and showed strong results when it came to data relating to manufacturability,” he said.

The researchers noted that one of the big challenges in the development of vaccines is the ability to produce them at sufficient scale for widespread use.

They said the phase 1 study being conducted in Queensland is progressing well and assuming the study demonstrates adequate safety and immune responses, data should be available in time to commence the required large-scale efficacy study before the end of the year.

📣 The Indian Express is now on Telegram. Click here to join our channel (@indianexpress) and stay updated with the latest headlines

For all the latest World News, download Indian Express App.

0 Comment(s) *
* The moderation of comments is automated and not cleared manually by indianexpress.com.
Advertisement
Advertisement
Advertisement
Advertisement